Greater efficacy of alfacalcidol in the red than in the yellow marrow skeletal sites in adult female rats

Journal of Musculoskeletal Neuronal Interactions

Volumn 8, Issue 3, 2008, Pages 257-266

  Tian, X Y ^a   Liu, X Q ^a   Chen, H Y ^a   Setterberg, R B ^a   Li, M ^b   Jee, Webster S S ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

Alfacalcidol; Distal tibia; Fatty (yellow) marrow site; Hematopoietic (red) marrow site; Histomorphometry; Proximal femur

Indexed keywords

ALFACALCIDOL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; BONE MASS; BONE STRUCTURE; CANCELLOUS BONE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; FEMUR; HEMATOPOIESIS; LUMBAR SPINE; METAPHYSIS; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; RAT; TIBIA; TRABECULAR BONE; TREATMENT DURATION; VERTEBRA BODY;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE MARROW; BONE REMODELING; BONE RESORPTION; CALCIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEMUR; HEMATOPOIESIS; HYDROXYCHOLECALCIFEROLS; ORGAN SIZE; OSTEOGENESIS; PHOSPHORUS; RATS; RATS, SPRAGUE-DAWLEY; TIBIA;

EID: 56749184949     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Ito H, Ke HZ, Jee WSS, Sakou T. Anabolic responses of an adult cancellous bone site to prostaglandin E2 in the rat. Bone Miner 1993;21:219-36.
2. Ma YF, Ke HZ, Jee WSS. Prostaglandin E2 adds bone to a cancellous bone site with closed growth plate and low turnover in ovariectomized rats. Bone 1994;15:133-46.
3. Jee WS, Ma YF. The in vivo anabolic actions of prostaglandins in bone. Bone 1997;21:297-304.
4. Li M, Liang H, Shen Y, Wronski TJ. Parathyroid hormone stimulates cancellous bone formation at skeletal sites regardless of marrow composition in ovariectomized rats. Bone 1999;24:95-100.
5. Pun S, Dearden RL, Rathus AM, Liang H, Wronski TJ. Decreased bone anabolic effect of basic fibroblast growth factor at fatty marrow sites in ovariectomized rats. Bone 2001;28:220-6.
6. Chen HY, Tian XY, Liu XQ, Setterberg RB, Li M, Jee WSS. Alfacalcidol stimulated focal bone formation on the cancellous surface and increased periosteal bone at the lumbar vertebra of adult female rats. Calcif Tissue Int 2008;82:127-36.
7. Liu XQ, Chen HY, Tian XY, Setterberg RB, Li M, Jee WSS. Alfacalcidol treatment increases bone mass and strength from anti-catabolic and anabolic effects on cancellous and cortical bone in intact female rats. J Bone Miner Metab 2008;26:425-35.
8. Wickramasinghe SN. Human Bone Marrow. Oxford: Blackwell Scientific; 1975.
9. Dawson AB. The age order epiphyseal union in the long bones of the albino rat. Anat Rec 1925;31:1-17.
10. Okumura H, Yamamuro T, Kasai R, Hayashi T, Tada K, Nishii Y. Effect of 1 alpha-hydroxyvitamin D3 on osteoporosis induced by immobilization combined with ovariectomy in rats. Bone 1987;8:351-5.
11. Geusens P, Dequeker J, Nijs J, Verstraeten A, Bramm E. Prevention and treatment of osteopenia in the ovariectomized rat: effect of combined therapy with estrogens, 1-alpha vitamin D, and prednisolone. Calcif Tissue Int 1991;48:127-37.
12. Shiraishi A, Higashi S, Ohkawa H, Kubodera N, Hirasawa T, Ezawa I, Ikeda K, Ogata E. The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif Tissue Int 1999;65:311-6.
13. Matsunaga S, Ito H, Sakou T. The effect of vitamin K and D supplementation on ovariectomy-induced bone loss. Calcif Tissue Int 1999; 65:285-9.
14. Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto T, Ogata E. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res 2000;15:770-9.
15. Nishikawa T, Ogawa S, Kogita K, Manabe N, Katsumata T, Nakamura K, Kawaguchi H. Additive effects of combined treatment with etidronate and alfacalcidol on bone mass and mechanical properties in ovariectomized rats. Bone 2000;27:647-54.
16. Shiraishi A, Higashi S, Masaki T, Saito M, Ito M, Ikeda S, Nakamura T. A comparison of alfacalcidol and menatetrenone for the treatment of bone loss in an ovariectomized rat model of osteoporosis. Calcif Tissue Int 2002;71:69-79.
17. Ito M, Azuma Y, Takagi H, Komoriya K, Ohta T, Kawaguchi H. Curative effect of combined treatment with alendronate and 1 alpha-hydroxyvitamin D3 on bone loss by ovariectomy in aged rats. Jpn J Pharmacol 2002;89:255-66.
18. Li M, Healy DR, Simmons HA, Ke HZ, Thompson DD. Alfacalcidol restores cancellous bone in ovariectomized rats. J Musculoskelet Neuronal Interact 2003;3:39-46.
19. Iwamoto J, Seki A, Takeda T, Sato Y, Yamada H, Yeh JK. Comparative effects of alendronate and alfacalcidol on cancellous and cortical bone mass and bone mechanical properties in ovariectomized rats. Exp Anim 2006;55:357-67.
20. Iwamoto J, Seki A, Takeda T, Sato Y, Yamada H, Yeh JK. Therapeutic effect of risedronate on cancellous and cortical bone in ovariectomized osteopenic rats: a comparison with the effects of alfacalcidol. Exp Anim 2006;55:333-42.
21. Shiraishi A, Ito M, Hayakawa N, Kubota N, Kubodera N, Ogata E. Calcium supplementation does not reproduce the pharmacological efficacy of alfacalcidol for the treatment of osteoporosis in rats. Calcif Tissue Int 2006;78:152-61.
22. Li M, Shen Y, Wronski TJ. Time course of femoral neck osteopenia in ovariectomized rats. Bone 1997;20:55-61.
23. Li M, Wronski TJ. Response of femoral neck to estrogen depletion and parathyroid hormone in aged rats. Bone 1995;16:551-7.
24. Jee WSS, Inoue J, Jee KW, Haba T. Histomorphometric assay of the growing long bone. In: Takahashi H, editor Handbook of Bone Morphology. Niigata City: Nishimura Co., Ltd.; 1983. p. 101-122.
25. Parfitt AM, Matthews CHE, Villanueva AR, Kleerekoper M, Frame B, Rao DS. Relationships between surface, area and thickness of iliac trabecular bone in aging and in osteoporosis. J Clin Invest 1983; 72:1296-1409.
26. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 1987;2:595-610.
27. Compston JE, Mellish RWE, Garrahan NJ. Age-related changes in iliac crest trabecular microanatomic bone structure in man. Bone 1987;8:289-92.
28. Compston JE, Mellish RWE, Croucher P, Newcombe R, Garrahan NJ. Structural mechanisms of trabecular bone loss in man. Bone Miner 1989;6:339-50.
29. Hauge E, Mosekilde L, Melsen F. Missing observations in bone histomorphometry on osteoporosis: implications and suggestions for an approach. Bone 1999;25:389-95.
30. Li XJ, Jee WSS, Li YL, Patterson-Buckendahl P. Transient effects of subcutaneously administered prostaglandin E2 on cancellous and cortical bone in young adult dogs. Bone 1990;11:353-64.
31. Li XJ, Jee WSS, Ke HZ, Mori S, Akamine T. Agedrelated changes of cancellous and cortical bone histomorphometry in female Sprague-Dawley rats. Cells and Materials 1991;1(Suppl.):25-35.
32. Ma Y, Chen YY, Jee WSS, Ke HZ, Ijiri K. Co-treatment of PGE2 and risedronate is better than PGE2 alone in the long-term treatment of ovariectomized-induced osteopenic rats. Bone 1995;17(Suppl.):S267S-72.
33. Tian XY, Zhang Q, Zhao R, Setterberg RB, Zeng QQ, Ma YF, Jee WS. Continuous PGE2 leads to net bone loss while intermittent PGE2 leads to net bone gain in lumbar vertebral bodies of adult female rats. Bone 2008;42:914-20.
34. Erben RG. Vitamin D analogs and bone. J Musculoskelet Neuronal Interact 2001;2:59-69.
35. Li M, Healy DR, Li Y, Simmons HA, Su M, Jee WS, Shen VW, Thompson DD. Alfacalcidol prevents agerelated bone loss and causes an atypical pattern of bone formation in aged male rats. J Musculoskelet Neuronal Interact 2004;4:22-32.
36. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL, Shanahan CM. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004;15:2857-67.
37. Razzaque MS, St. Arnaud R, Toguchi T, Lanske B. FGF-23, vitamin D and calcification: the unholy triad. Nephrol Dial Transplant 2005;20:2032-5.
38. Towler DA. Vascular calcification: a perspective on an imminent disease epidemic. IBMS BoneKEy 2008;5:41-58.
39. Kobayashi S, Takahashi HE, Ito A, Saito N, Nawata M, Horiuchi H, Ohta H, Ito A, Iorio R, Yamamoto N, Takaoka K. Trabecular minimodeling in human iliac bone. Bone 2003;32:163-9.
40. Lindsay R, Cosman F, Zhou H. Bostrom MP, Shen VW, Cruz JD, Nieves JW, Dempster DW. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 2006;21:366-73.
41. Ma YL, Zeng Q, Donley DW, Ste-Marie LG, Gallagher JC, Dalsky GP, Marcus R, Eriksen EF. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 2006;21:855-64.
42. Hansen CM, Hansen D, Holm PK, Binderup L. Vitamin D compounds exert anti-apoptotic effects in human osteosarcoma cells in vitro. J Steroid Biochem Mol Biol 2001;77:1-11.
43. Duque G, El Abdaimi K, Henderson JE, Lomri A, Kremer R. Vitamin D inhibits Fas ligand-induced apoptosis in human osteoblasts by regulating components of both the mitochondrial and Ras-related pathways. Bone 2004;35:57-64.
44. Riggs GL, Parfitt AM. Perspective. Drugs used to treat osteoporosis. The critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 2005;20:177-84.
45. Li M, Shen Y, Qi H, Wronski TJ. Comparative study of skeletal response to estrogen depletion at red and yellow marrow sites in rats. Anat Rec 1996;245:472-80.
46. Aubin JE, Lean JB, Stein GS. Bone formation: maturation and functional activities of osteoblast lineage cells. In: Primer on the Metabolic Bone Disease and Disorders of Mineral Metabolism, Sixth Edition. Washington DC: American Society for Bone and Mineral Research; 2006. p. 20-29.
47. Branemark P. Vital microscopy of bone marrow in rabbit. Scand J Clin Lab Invest 1959;11(Suppl.38)1-82.
48. Van Dyke D. Similarity in distribution of skeletal blood flow and erythropoietic marrow. Clin Orthop 1967;52:37-51.
49. Gross PM, Heistad DD, Marcus ML. Neurohumoral regulation of blood flow to bones and marrow Am J Physiol 1979;237:440-8.
50. Kuznetsov SA, Mankami MH, Gronthos S, Satomura K, Dianco P, Robey PG. Circulating skeletal stem cells. J Cell Biol 2001;153:1133-40.
51. Eghbali-Fatourechi GZ, Lamsam J, Fraser D, Nagel D, Riggs BL, Khosia S. Circulating osteoblast-lineage cells in humans. N Engl J Med 2005;352:1959-66.
52. Brandi ML, Collin-Osdoby P. Vascular biology and the skeleton. J Bone Miner Res 2006;21:183-92.
53. Wronski TJ, Smith JM, Jee WSS. Variations in mineral apposition rate of trabecular bone within the beagle skeleton. Calcif Tissue Int 1981;33:583-6.
54. Eriksen EF, Eghbali-Fatourechi GZ, Khosla S. Remodeling and vascular spaces in bone. J Bone Miner Res 2007;22:1-6.
55. Hauge Em, Qvesel D, Eriksen EF, Mosekilde L, Melsen F. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res 2001;16:1575-82.
56. Centrella M, McCarthy TL, Canalis E. Transforming growth factor-beta and remodeling of bone. J Bone Joint Surg Am 1991;73:1418-28.
57. Baylink DJ, Finkelman RD, Mohan S. Growth factors to stimulate bone formation. J Bone Miner Res 1993;8(Suppl.2):S565-72.
58. Mundy GR, Bonewald LF. Role of TGF beta in bone remodeling. Ann NY Acad Sci 1990;593:91-7.
59. Karsdal MA, Marin TJ, Bollerslev J, Christiansen C, Henriksen K. Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res 2007;22:487-94.
60. Miller SC, Bowman BM, Smith JM, Jee WSS. Characterization of endosteal bone-lining cells from fatty bone sites in adult beagles. Anat Rec 1980;198:163-73.
61. Miller SC, Jee WSS. The bone forming cells: Origin, distribution proliferation and differentiation. In: Takahashi HE, editor. Bone Morphometry. Niigata: Nishimura and London: Smith-Gordon; 1988. p. 29-36.
62. Hodsman AB, Steer BM. Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: evidence for de novo bone formation on quiescent cancellous surfaces. Bone 1993;14:523-7.
63. Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995;136:3632-8.
64. Leaffler D, Sweeney M, Kellerman LA, Avnur Z, Krstenasky JL, Vicery BH, Caufield JP. Modulation of osteogenic cell ultrastructure by RS-23581, an analog of human parathyroid hormone PTH-related peptide (1-34) and bovine PTH (1-34). Endocrinology 1995;136:3624-31.
65. Hodsman AB, Habnley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003;88:5212-20.
66. Gasser JA. Coupled or uncoupled remodeling, is that the question? J Musculoskelet Neuronal Interact 2006;6:128-33.